NYSE: BTI$ 40.93(0.245)
Our purpose is clear: Build A Better Tomorrow™.
Tobacco products exist on a continuum of risk to the consumer’s health, with combustible cigarettes being the riskiest.
At Reynolds, we put science first, focusing our nicotine and tobacco science research and technology efforts on potentially reduced-risk products as we accelerate our Tobacco Harm Reduction efforts to reduce the health impact of our business.
We operate in a broad spectrum of scientific fields including molecular biology, toxicology, and chemistry as we assess the reduced-risk potential of our products. It is essential that these products are backed by strong science and that science is peer-reviewed by the scientific community.
We are building the foundation for non-combustible products through robust science, including our 9-Step Framework to assess the risk of our products. Our framework includes scientific studies starting from small-scale studies at the laboratory bench all the way up to large-scale studies examining the effect of our products on public health.
For more in-depth information on our science please visit:
Collaboration is at the heart of some of the most groundbreaking scientific advancements in history. Take for instance, the discovery of DNA’s double helix structure by Watson, Crick, and the contributions of Maurice Wilkins and Rosalind Franklin. This was a product of pure teamwork, collective knowledge, and a shared effort for human progression. Collaboration, especially … Continued
Recently you have probably started to hear a lot about Tobacco Harm Reduction or “THR” from us and moving forward, you’re going to hear a lot more. THR is an approach to improve public health outcomes by focusing on what we believe is one of the most important movements for America’s health agenda – … Continued
Recently, the National Youth Tobacco Survey (NYTS) results were released, which showed the continued decline in youth e-cigarette (Vapor Products) use, which is now at the lowest level in a decade, and down 71% since its peak in 2019. At Reynolds American, underage access prevention (UAP) is more than a policy; it is … Continued
I firmly believe in what we’re doing in the tobacco harm reduction space. I think being able to offer potentially reduced-risk products that will reduce exposure to harmful chemicals is a huge offering for the US population.
-Sarah Baxter-Wright, VP of Science
Our team of world-class researchers and scientists provided robust evidence throughout the year to support our New Category products in THR. In 2023 alone, we produced 19 publications and 35 key presentations.
The key themes across these publications were THR and strengthening scientific positions for alternative products. Conferences attended by our team included the Food & Drug Law Institute Tobacco and Nicotine Product Regulatory Science Symposium, Next Generation Nicotine Delivery, and the Cooperation Centre for Scientific Research Relative to Tobacco.